Edwards Lifesciences, TAVR and Stifel
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.13 which represents a decrease of $-1.43 or -1.97% from the prior close of $72.56. The stock opened at $72.5 and touched a low ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
周四，Stifel分析师将Edwards Lifesciences股票评级从持有上调至买入，理由是经导管主动脉瓣置换（TAVR）市场的潜在增长加速。该公司还将Edwards Lifesciences的目标价从$75.00上调至$90.00。根据 InvestingPro 数据，Edwards Lifesciences目前市值为$41.95 ...
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback